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Multiple Myeloma (MM) is an incurable haematological malignancy characterised by the 
uncontrolled outgrowth of clonal plasma cells and is preceded by the premalignant phase, monoclonal 
gammopathy of undetermined significance (MGUS). It is currently unknown what drives MGUS-to-
MM transition; however, recent studies suggest exogenous factors within the bone marrow (BM) 
microenvironment play a pivotal role. Notably, MGUS has been associated with skeletal fragility, 
with an increased risk of fractures. Myeloperoxidase (MPO) is an enzyme abundantly deposited at 
sites of fracture by infiltrating neutrophils. Recent studies have elucidated novel roles for MPO in 
tumorigenesis, however it is yet to be implicated in the context of MM. We aimed to evaluate the role 
of MPO in driving MM progression, utilising in vitro proliferation and migration models, and the 
well-characterised C57Bl/KaLwRij/5TGM1 mouse model of MM. 
In KaLwRij mice, induced intratibial damage with heightened MPO activity, enhanced 5TGM1 MM 
cell homing to the site of injury (p=0.0045). Interestingly, we show that MPO significantly 
upregulates the mRNA expression of major MM growth factors, IL-6 and VEGF in both human and 
murine BM stromal cells. Furthermore, MPO stimulated BM stromal cells significantly increased 
murine (p=0.000019) and human (p=0.0087) MM cell proliferation. Additionally, MPO promoted 
5TGM1 cell migration in vitro (p=0.038) and induced cell signal transduction. Finally, in the 
KaLwRij/5TGM1 model, injected MPO significantly enhanced tumour burden within the tibia BM 
by 16% after 24 days (p=0.048). Collectively, these findings suggest that MPO may be a viable 
therapeutic target in limiting the progression from MGUS to active MM. 
 







Multiple Myeloma (MM) is an incurable haematological malignancy of the plasma cells (PC) within 
the bone marrow (BM)1. MM is the second most common haematological malignancy with a global 
5-year prevalence of 230,000 patients with the median age of approximately 70 years2,3. MM is 
characterised by the dysregulation of monoclonal PC proliferation, consequentially resulting in the 
overproduction of immunoglobulins and immunoglobulin light chains which lack any known 
function1, 4.  MM diagnosis requires >10% of clonal plasma cells within the BM, accompanied by the 
presence of one or more features of end stage organ damage often referred to as ‘CRAB’ features 
(hypercalcemia, renal failure, anemia, lytic bone lesions)5. MM is preceded by a premalignant 
condition known as monoclonal gammopathy of undetermined significance (MGUS). MGUS is a 
disorder, characterised by <10% BM PC and the absence of the end stage organ damage seen in MM6, 
7. Current treatment of MGUS consists of a ‘wait and see approach’, which involves regular screening 
until evidence of MM features manifest. Patients with MGUS often maintain stable levels of clonal 
PC for extended periods of time. However, in approximately 1% of patients annually, MGUS 
progresses to MM due to unknown pathophysiological mechanisms7, 8..Until recently, progression of 
MM from MGUS was thought to be a result of the gradual acquisition of driver mutations within the 
abnormal PC clones6, 9. However, recent studies conducted by Dutta and colleagues, which utilized 
whole exome sequencing of PC samples collected from patients with MGUS who subsequently went 
on to develop MM, were successful in identifying that disease progression is predominantly 
associated with the outgrowth of PC clones already present at the MGUS stage10. Moreover, recent 
studies using transgenic mice engineered to express MM PC growth factors have shown that 
intrafemoral xenografts of PC from MGUS patients were as capable of engraftment as PC from 
symptomatic MM patients, suggesting that MGUS PC have the same proliferative potential as MM 
PC, if provided with a growth supportive BM microenvironment11. These findings suggest that rather 
than acquisition of new genetic mutations triggering the dysregulation of clonal PC proliferation, the 
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progression from MGUS to MM may be largely regulated by changes within the BM 
microenvironment. 
 
A number of recent studies have identified that patients with MGUS often acquire skeletal fragility, 
coinciding with a substantially increased risk of bone fracture12-14. The fracture healing process is 
made up of a complex of regenerative physiological processes, with immune cells playing a pivotal 
role, in particular, neutrophils15. Neutrophils have been widely observed as the most abundant cell 
type in the early fracture hematoma16. Myeloperoxidase (MPO) is a heme containing peroxidase 
enzyme, expressed in abundance by neutrophils, constituting up 5% of the cells dry mass. In the 
presence of hydrogen peroxide (H2O2), MPO oxidizes chloride ions, to generate hypochlorous acid 
which has been shown to have potent antimicrobial properties17, 18 19. Interestingly, neutrophil 
infiltration and accumulation within tumour sites has largely been associated with poorer patient 
prognosis and increased disease burden20,21. Recent studies have elucidated new roles for MPO on 
multiple cell types driving fibroblastic, osteoblastic, and vascular cell functions22, 23. Moreover, MPO 
has been shown to be overexpressed in patients with leukemia, as well as abundantly deposited in 
breast cancer 24, 25. Strikingly,  in a well-characterised mouse model of breast cancer, direct MPO 
stimulation was shown to have a causative role in driving breast cancer progression via regulation of 
the tumour microenvironment, with an increase in collagen deposition, vascularization, and a 
concomitant increase in lung metastasis23.  
 
Notably, IL-6 is highly upregulated in the serum of MM patients and to date has been well 
characterised as a significant growth factor for myeloma plasma cells26. Interestingly, IL-6 production 
is increased in older patients in response to fractures compared to their younger counterparts and is a 
key driver of MM pathogenesis27. In addition to its direct proliferative effects on MM cells, IL-6 acts 
through aiding in the progression of the disease through enhancing the vascularization within the 
bone marrow28. IL-6 is also is known to promote angiogenesis in MM through the enhancement of 
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vascular endothelial growth factor (VEGF)29.  Enhanced vascularity is considered a hallmark of MM 
and has been has been well characterised  as a negative prognostic factor30. Furthermore, MPO was 
recently identified as a driver of angiogenesis with reported increases in expression of both VEGF 
and IL-6 in human endothelial cells22. Therefore, MPO deposited at sites of fracture may play a role 
in regulating the bone marrow microenvironment, subsequentially creating a niche which facilitates 






















HYPOTHESIS AND AIMS 
We hypothesize that increased deposition of myeloperoxidase by inflammatory cells at sites of bone 
damage and/or fractures creates a permissive tumor microenvironment for MGUS plasma cells to 













Figure 1. Hypothesis regarding MPO deposition within sites of bone fracture 
 
This hypothesis will be addressed through the following aims: 
1. To determine whether induced inflammation with an increase in MPO activity within the bone 
marrow increases MM homing. 
2. To determine the role of MPO on MM proliferation and migration in vitro and examine the 
mechanisms and signaling pathways involved 
3. To investigate the effect of MPO deposition in MM development and progression using in vivo 
models of MM. 
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MATERIALS AND METHODS 
Cell Culture 
All tissue culture reagents used were manufactured by Sigma Aldrich (St. Louis, MO, USA) unless 
otherwise specified. Cells were cultured under sterile conditions, maintained at 37˚C in the presence 
of 5% CO2. All media was supplemented with 10,000 U/mL penicillin, 10 mg/ml streptomycin, 200 
mM L-glutamine, 100 mM sodium pyruvate and 1 mM HEPES. Murine 5TGM1 myeloma cell line 
was cultured in complete Iscove’s modified Dulbecco’s medium (IMDM) supplemented with 20% 
foetal calf serum (FCS). Human OPM-2 myeloma cell line was maintained in Roswell Park Memorial 
Institute Medium (RPMI-1640), supplemented with 10% FCS. Murine OP9 stromal cells and Human 
Osteoblast (NHB) stromal cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
– high glucose supplemented with 10% FCS.  
 
Animals 
Age and sex matched C57Bl/KaLwRij mouse were housed at the South Australian Health and 
Medical Research Institute (SAHMRI) within Bio-resources under pathogen free conditions. 
Experimental work and intervention were carried out in accordance with the University of Adelaide 
and SAHMRI ethics.  
 
Mouse Models of MM  
Acute tibial injury and direct recombinant MPO injection (10µg) was achieved via insertion of a 26-
gauge intubator into the medullary cavity. To detect MPO activity, mice were injected with 125µL 
of luminol (40mg/mL in PBS, Sigma) and imaged using an IVIS Spectrum imaging system (Caliper, 
Almameda, CA).  For intravenous (i.v.) model, 5x106 luciferase-expressing GFP+ 5TGM1 cells, 
resuspended in 100µL of PBS were injected through the tail vein of 6-8 week old C57Bl/KaLwRij. 
Mice were subject to regional hindlimb BLI, in addition to endpoint flow cytometry of GFP+ tumour 
cells in complete marrow harvested from tibias as previously described31. To asses tumour burden, 
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mice were administered with firefly D-Luciferin (30 mg/ml in PBS, Biosynth). Mice were subject to 
regional hindlimb BLI. At the study endpoint, complete marrow was harvested from tibias and 
analysed for GFP+ tumour cells via flow cytometry as previously described32. 
 
Transwell Migration  
MM PC migration was determined in vitro using 24 well transwell plate (BD Falcon FluoroBlokTM) 
system, encompassing PET membranes with 8.0µm pores (n=2). GFP+ 5TGM1 cells were serum-
starved in 1% FCS IMDM for 1 hour prior to 5x105 cells in 100 µL being transferred into the upper 
chamber of the transwell. 600 µL of normal cell culture media at varying concentrations of MPO 
(0.25 µg/mL, 0.5 µg/mL, 1 µg/mL) was added to the lower chamber. Cells were allowed to migrate 
for 24 hr with 20% FCS IMDM culture media acting as the vehicle control. Migrated GFP+ 5TGM1 
cells were photographed and quantified using a fluorescent microscope as previously described33.  
 
RNA Isolation & Quantitative Real-Time Polymerase Chain Reaction (RT-PCR) 
Murine OP9 and human NHB BM stromal cells were seeded into 6 well plates and were cultured in 
serum-free DMEM cell culture media acting as the vehicle control or supplemented with 
Myeloperoxidase at indicated concentrations (n=1). Total RNA was extracted using TRIzol (Life 
Technologies, Calsbad, CA, USA) after 24 hours. After isolating RNA, Superscript IV was used to 
synthesize cDNA as previously described.34 Quantification of gene expression was achieved through 
RT-PCR using SYBR-Green Fluor qPCR mastermix on a Biorad CFX Connect as previously 
described.23 Samples were run in triplicate, with gene expression presented as fold change compared 
to the vehicle control. Primer pairs: human IL6 5’- ACAGACAGCCACTCACCT-3’ (forward), 5’-
TTTCACCAGGCAAGTCTCCT-3’ (reverse); human VEGF 5-ATGCCAAGTGGTCCCAGG-3’ 
(forward), 5’-CACACAGGATGGCTTGAAGA-3’ (reverse); human β-actin 5’-
GATCATTGCTCCTCCTGAGC -3’ (forward) 5’- GTCATAGTCCGCCTAGAAGCAT-3’ 
(reverse); murine Il6 5’- GCCTTCTTGGGACTGATGCT-3’ (forward) 5’-
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CTGCAAGTGCATCATCGTTGT-3’ (reverse); murine Gapdh 5’-TGCACCACCAACTGCTTAG-
3’ (forward) 5’-GGATGCAGGGATGATGTTC-3’ (reverse). 
 
IL-6 Enzyme Linked Immunosorbent Assay (ELISA) 
To evaluate the effect of MPO stimulation on stromal cell production of IL-6, human stromal cells 
were seeded into 96 well plates at a density of 1x104 cells/well in 100 µl 10% FCS DMEM and were 
allowed to culture for 5 days until reaching confluence. Media was removed and cells were stimulated 
for 24, 48 and 72 hr in serum-free DMEM containing MPO, or serum-free DMEM cell culture media 
acting as the vehicle control. At the end of each stimulation period, supernatant was collected to allow 
the measurement of soluble IL-6 by ELISA. The amount of soluble IL-6 in the supernatant was 
measured using a Quantikine ELISA Human IL-6 Immunoassay (R&D Systems, Inc. USA), as per 
manufacturer’s instructions, using a standard curve formulated from recombinant human IL-6. 
 
In Vitro Conditioned Media - MM Proliferation 
Murine OP9 or human NHB stromal cells (n=2) were seeded (2x105) into T25 cell culture flasks and 
were allowed to grow to confluency in 10% FCS DMEM, with media changes 2-3 times per week. 
Stroma was then stimulated with recombinant human MPO at increasing concentrations (0.25 µg/mL, 
0.5 µg/mL, 0.75 µg/mL, 1 µg/mL, 1.5 µg/mL) in 2 mL of 1%FCS IMDM for 48 hr, 1% FCS IMDM 
served as the vehicle control. Conditioned media was then collected and mixed at a ratio of 50:50. 
5TGM1 cells were seeded in 20% FCS IMDM final, in corresponding OP9 conditioned media, whilst 
OPM2 cells were seeded in 10% FCS RPMI final in corresponding NHB conditioned media for 24 




IHC staining for MPO and GFP was performed on mouse formalin fixed paraffin embedded femurs. 
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Samples were subjected to heat-induced antigen retrieval (10 mM citrate buffer (pH 6)) at 97°C for 
30 minutes, followed by endogenous peroxidase inactivation for 30 mins at room temperature using 
0.5% H2O2 in methanol. To prevent non-specific binding of antibodies, slides were incubated with 
3% normal goat serum 0.2% bovine serum albumin in PBS for 1 hr. Sections of tissue were incubated 
with primary antibodies (MPO (GA511, DAKO, Ready-to-use); and GFP (A6455, ThermoFisher, 
1:1000) overnight. The following day slides were incubated with either EnVision/FLEX (DAKO, 
GV800;MPO) or anti-rabbit IgG biotin (Vector Labs, BA-1000;GFP) for 30 mins, followed by 1hr 
incubation with streptavidin-HRP (Vector Laboratories;GFP). Slides were developed using DAB 
(Vector Laboratories), counterstained with haematoxylin, and visualised using a light microscope 
(Eclipse 90i; Nikon).  
 
MPO Immunofluorescence  
Murine 5TGM1 myeloma plasma cells were seeded at a density of 5x105 cells/ well into a 6 well 
plate and stimulated with MPO (2 µg/mL) for either 20 min or 3 hr. Cells were resuspended in 100 
µL of neat FCS and placed into a cytocentrifuge to be spun onto slides for staining. NHB human 
stromal cells stimulated with MPO were used as the positive control. Each slide was washed 3x with 
PBS, before designated cells (Vehicle Control/ 3-hour timepoint) were permeated with 0.25% Triton 
X-100 in 1xPBS for 10 min. Slides were washed prior to blocking of nonspecific binding sites with 
3% BSA in PBS and a 1:10 dilution of non-immune goat serum for 90 min at room temperature. 
Slides were then incubated with primary rabbit anti-MPO antibody (Bioss Inc. Boston Massachusetts, 
USA) 1:100 dilution containing 1% BSA for 60 min at room temperature. Labelled proteins were 
then detected with 1:500 dilution of anti-rabbit IgG AlexaFluor594 in 1% BSA in PBS in the dark 





Western Blot Analysis  
Murine 5TGM1 myeloma plasma cells were seeded into T25 cell culture flasks and starved in serum-
free IMDM (0.5% FCS) overnight and then stimulated with indicated treatments for 5, 15 and 30 
min. Lysates were prepared as previously described36. Briefly, 50 µg of each lysate were separated 
using a 10% sodium dodecyl sulphate-polyacrimide gel, subjected to SDS-PAGE. Gels were 
transferred onto polyvinylidene difluoride membrane (PVDF, GE Healthcare). Immunoblotting was 
conducted using Anti-Phosphotyrosine clone 4G10® antibody (Millipore, Cat. No. 05-321, 1:1000 
dilution). α-Tubulin acted as the loading control. Protein signal was visualised using enhanced 




Statistical analyses were conducted using GraphPad Prism (Version 8 GraphPad Software Inc, CA, 
USA) and Image J. Data was analysed using Students unpaired t-test (two-sided). p<0.05 was deemed 














Myeloperoxidase promotes homing of murine MM PC in vivo.  
A striking feature of multiple myeloma is the ability of clonal MM PC to migrate and home to 
multiple bone microenvironments37. To evaluate whether inflammatory MPO deposition promotes 
myeloma plasma cell homing to the bone marrow, a localised inflammatory response was induced by 
performing a sham intratibial (i.t.) injection in the left tibia of male C57Bl/KaLwRij mice 24 hr prior 
to 5TGM1 tumour cell inoculation. The increase in localised MPO activity within the tibia was 
confirmed using luminol reagent (Fig 1A). Flow cytometry analysis of the harvested bone marrow 
revealed a significant increase (p=0.0045) in the number of GFP+ 5TGM1 MM cells present in the 



























Figure 2. Effect of increased MPO activity on murine 5TGM1 plasma cell homing. (A) Sham i.t. 
was performed in C57Bl/KaLwRij mice. Representative BLI (luminol) indicating MPO-activity at 
site of damage. (B) C57Bl/KaLwRij mice were injected with 5x106 GFP+ 5TGM1 cells in 100 µL of 
PBS via i.v. Flow cytometry was conducted on complete marrow from mice after 24 hr from the sham 
i.t. tibia in addition to the contralateral control leg. Quantified as total number of GFP+ cells per 
1x106 cells. Results are shown as the mean ± SEM, n=8 mice. Statistical significance determined 








MPO promotes migration of MM PC in vitro.          
To further examine the homing abilities of MPO in MM, we performed 5TGM1 plasma cell migration 
assays in vitro. GFP+ 5TGM1 cells were seeded in the the upper chamber of a BD Falcon 
FluoroBlokTM transwell insert, with increasing concentrations of MPO in normal culture media in the 
lower chamber. After 24 hours, 5TGM1 migration was significantly increased 4 fold toward MPO at 






















Figure 3. MPO independently promotes transwell migration of 5TGM1. (A) Transwell migration 
of GFP+ 5TGM1 cells after 24 hr. (B) Representative images of migrated GFP+ 5TGM1 cells. Cells 
were serum-starved in 1% FCS IMDM for 1 hr prior being seeded in the upper well of a transwell 
system. Migrated cells were photographed at 20x magnification and quantified using a fluorescent 
microscope. Scale bar 100µm. Mean ± SEM performed in triplicate, n=2. Statistical significance 








MPO upregulates protumorigenic factors in bone marrow stromal cells.  
MPO has previously been shown to regulate stromal cell gene regulation23.  As MM is reliant upon 
the stroma for survival and proliferation, we investigated whether MPO stimulated the upregulation 
of two major growth factors involved in MM progression, IL-6 and VEGF. Cultured murine OP9 and 
human NHB cells were stimulated with MPO at the concentrations indicated (Fig. 2A-B). RT-qPCR 
confirmed that MPO resulted in a maximal 13.1-fold (p=0.028) and 3-fold (p=0.033) increase in IL-
6, with an 8-fold (p=0.000051) and 2.4-fold (p=0.0016) increase in VEGF mRNA expression in OP9 
and NHB cell populations respectively. Furthermore, to determine whether the increase in IL-6 
expression exhibited in human NHB cells translated to protein synthesis, we performed an ELISA 
specific to human IL-6. We show that MPO at 0.5 µg/ml significantly increased soluble IL-6 secreted 
































Figure 4. Effect of MPO stimulation on mRNA expression of IL-6 and VEGF in murine OP9 and 
human NHB stromal cells. RT-qPCR analysis of mRNA IL-6 and VEGF expression in murine OP9 
(A) and human NHB (B) stromal cells. Gene expression was measured following 24 hr culture in the 
presence of MPO at the concentrations indicated. Normalised to Gapdh and β-actin respectively. (C) 
Soluble IL-6 produced by NHB cells in response to MPO after 24 hours, quantified using ELISA 
detection. Expressed as fold change relative to serum-free DMEM vehicle control.  Mean ± SD, 
performed in triplicate, n=1, previosuly confirmed in other cell populations. Statistical significance 






MPO promotes MM cell proliferation indirectly through interactions with BM stroma in vitro. 
There exists a complex interaction between MM tumour cells and the bone marrow stromal cells, and 
exposure to stromal cells enhances MM disease progression38. To explore the indirect role of MPO 
in driving myeloma plasma cell proliferation through interactions with the BM microenvironment, 
we investigated the proliferation of murine 5TGM1 and human OPM2 myeloma plasma cell lines in 
vitro supplemented with MPO-treated conditioned media. Conditioned media was generated by 
stimulating murine OP9 or human NHB cells in reduced-serum DMEM supplemented with MPO at 
varying concentrations for 48 hr prior to being collected. Proliferation 5TGM1 (p=0.000019) and 
OPM2 (p=0.0087) cell lines were significantly increased after 72 hr in the presence of MPO 


































Figure 5. Proliferation of murine 5TGM1 and human OPM2 myeloma plasma cells in response to 
supplementation with MPO stimulated BM stromal cell conditioned media. Proliferation after 24 
hr and 72 hr of murine 5TGM1 (A) and human OPM2 (B) cells cultured in supernatant collected from 
OP9 or NHB cells respectively, stimulated with MPO for 48 hr. Cells were incubated for 2 hr with 
addition of WST-1 reagent prior to quantification using colorimetric detection. Expressed as fold 
increase relative to the unstimulated control. Mean ± SEM performed in quadruplicate, n=2. 





MPO is present and active at sites of MM 
To investigate whether MPO is deposited within the tumour microenvironment in active MM, 
C57Bl/KaLwRij mice injected with luciferase-expressing 5TGM1 cells were subject to regional 
hindlimb BLI. MPO activity was detected through the use of luminol where it was found to be 
colocalized with sites of tumour. Furthermore, immunohistochemistry was performed on tissue 
sections of femurs isolated from C57Bl/KaLwRij mice injected with GFP+ 5TGM1 cells via i.v. 
Expression analysis of tumour burden femurs indicated strong expression of MPO, colocalized to 






































Figure 6. MPO expression is colocalized with 5TGM1 MM tumour in KaLwRij mice. (A) 
Representative BLI images indicating MPO activity indicated through luminol (i) and 5TGM1 
tumour (ii).  (B) Immunohistochemistry of femur sections taken from tumour naïve KaLwRij mice 
(i) or injected with 5TGM1 GFP+ cells via i.v. (ii), stained with MPO. Representative image of GFP 
indicating colocalization of MPO and GFP+ 5TGM1 cells. Images taken at 4x and 10x magnification. 
Positive signal indicated as dark brown staining.  
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MPO readily binds to the cell surface and is internalised by 5TGM1 cells, activating 
phosphotyrosine signaling pathways.  
To determine whether MPO interacts directly with MM plasma cells and mediate any potential 
mechanisms, murine 5TGM1 myeloma plasma cells were stimulated with MPO (2 µg/mL) for 20 
min or 3 hr. Immunofluorescence studies showed that MPO readily binds to the surface of 5TGM1 
cells within min (Fig 5A; Surface), as well as being taken up intracellularly after 3 hr (Fig 5A; 
Intracellular). No fluorescence was evident in the vehicle control, confirming the specificity of the 
MPO immunostaining. Furthermore, MPO stimulated phospho-tyrosine signalling within 5TGM1 








































Figure 7. MPO directly interacts with murine 5TGM1 cells in vitro, activating signalling pathways 
involved in tyrosine phosphorylation.  (A) Cultured 5TGM1 cells were stimulated with MPO for 
either 20 min or 3 hr and transferred to slides with a cytospin centrifuge. Cells were fixed, 
permeabilized (intracellular only) and stained for MPO localization. Surface images (40x), 
intracellular (60x) (B) Cultured 5TGM1 cells were stimulated with MPO for 5, 15 and 30 min at the 
concentrations indicated. Cell lysates were prepared and then subjected to western blot analysis with 






Direct intratibial injection of MPO promotes proliferation of 5TGM1 cells in vivo.   
To evaluate the role of MPO in MM progression, a luciferase-expressing, GFP+ murine 5TGM1 
myeloma plasma cell line was utilized in the C57Bl/KaLwRij animal model of MM. Mice were 
injected with MPO (10 µg) via intratibial injection. After 72 hours, 5TGM1 cells were administered 
intravenously. Tumour progression was monitored weekly using BLI. Tumour burden was quantified 
through luciferase intensity (photons/second). Although statistical significance was not detected 
using BLI (Fig.8B), a positive trend is observed in the MPO injected leg compared to the contralateral 
leg after 24 days (p=0.10). Flow cytometry conducted on complete tibia marrow collected at day 27 
indicated a significant increase in %GFP+ cells in MPO injected tibias when compared to the 

































Figure 8. Effects of direct IT injection of MPO on 5TGM1 tumour progression in KaLwRij mice. 
(A) Representative BLI images. MPO was administered via IT injection (10µg), with cells injected 
IV 72 hours post IT. Tumour burden expressed as total flux (photons per second) using BLI (B). Flow 
cytometry was conducted on complete marrow collected at day 26 from the MPO injected tibia and 
to the contralateral tibia which acted as the control. Quantified as percentage of 5TGM1 GFP+ cells 








The studies described herein provide exciting new data contributing to our ever-increasing 
understanding of the complex interplay between MM cells and the bone marrow microenvironment.  
Inflammation has been shown to play a critical role in the pathogenesis and progression of multiple 
cancer types, however, little is known about the interaction between inflammation and MM disease39, 
40. The present study demonstrates that inflammatory MPO may play a causative role in MM 
progression. To date, it is currently unknown what drives the shift causing premalignant MGUS 
patients to progress to active MM disease. Recent findings have identified that exogenous factors and 
alterations within the bone marrow environment are likely to play a pivotal role in driving this 
transition10, 11. With recent studies associating MGUS with skeletal fragility, interest surrounds how 
deposition of inflammatory MPO at sites of fracture may influence MGUS plasma cells and drive 
progression. MPO has been recently reported to drive extracellular matrix production and 
angiogenesis, processes well characterised in tumorigenesis22, 23, 34.  
 
The first aim of this study was to investigate the homing capacity of MM cells to bone with increased 
inflammation and MPO activity. We show that in KaLwRij mice, murine 5TGM1 plasma cell homing 
is significantly increased to sites of damage caused by a sham i.t. injection after 24 hours. 
Interestingly, a population based study with over 14,000 MM patients revealed that MM patients with 
bone fractures at the time of MM diagnosis are at a 28% higher risk of succumbing to the disease41. 
Furthermore, our in vitro migration data shows that MPO can independently stimulate 5TGM1 
migration. This finding coincides with other studies reporting the migratory effects of peroxidase 
enzymes, including MPO on fibroblasts, endothelial cells, and breast cancer cells22, 23. These results 
suggest that MPO has the capacity to increase the homing and migratory mechanism of MM cells and 
the likelihood of MGUS plasma cells migrating to sites of fractures, where they are susceptible to 
further outgrowth.   
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Multiple myeloma plasma cells rely upon stromal cell contact and soluble factors released by the 
stromal microenvironment for their survival, growth, and progression. Studies by Panagopoulos and 
colleagues previously reported that MPO promotes the progression of breast cancer through 
regulation of the stromal microenvironment23. Therefore, the second aim of this study was to 
investigate how MPO interacts with the stroma to promote MM progression in vitro. We identified 
that expression of VEGF, the primary growth factor for endothelial cells, and an essential contributor 
to vascularisation was significantly upregulated in both human and murine BM stromal cell 
populations in response to stimulation with MPO42. Taken collectively, our findings are consistent in 
highlighting the ability of MPO to independently promote angiogenesis as formerly described, 
creating a permissive microenvironment for MM cell expansion22.  Moreover, in numerous 
malignancies, including MM, high serum concentrations of IL6 have been associated with poor 
patient prognosis28, 43. MPO stimulation increased production of soluble IL-6, an inflammatory 
cytokine well characterised to drive MM through both modulation of VEGF as well as promoting 
MM plasma cell proliferation directly28, 44. Furthermore, we were successful in implicating MPO does 
indeed drive MM cell proliferation indirectly through interactions with stroma in vitro using both 
murine and human cell populations. However, direct MPO stimulation failed to show any 
proliferative effects on MM cells (data not shown). Therefore, MPO’s effects on MM proliferation is 
due to manipulating the stroma to create a permissive niche in which MM cells can thrive. 
 
Given our IHC findings which identified MPO to be abundantly present at sites of myeloma, we 
further showed that MPO is readily taken up and internalised by MM cells, activating signalling 
pathways involved in the phosphorylation of tyrosine residues. While there exists a vast number of 
molecular pathways in MM cells, using a pan-phosphotyrosine antibody, we identified that MPO 
profoundly activates this signal transduction pathway45.  A number of signalling pathways implicated 
in tyrosine phosphorylation have been well described in poor patient prognosis of MM such as 
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ERK1/2 and JAK/STAT, with further exploration needed to identify whether this interaction may be 
implicated in the context of MM progression46, 47. 
  
The final aim of this study was to determine whether MPO directly released within bone marrow 
microenvironment could promote MM progression. Direct injection of MPO into the bone marrow 
space before tumour cell inoculation significantly increased myeloma tumour burden by 16% 
compared to the contralateral tibia after 24 days. Rymaszewski and colleagues have previously  
indicated specific inhibition of the catalytic function of MPO, resulted in a reduced tumour burden of 
up to 50% in a murine model of lung carcinoma, suggesting inhibition of MPO may prove a viable 
complimentary therapeutic in limiting MM progression48.   
 
Collectively, our findings demonstrate that MPO has the potential to play a functional role in driving 
MGUS to MM transition through interactions with the bone marrow microenvironment and potential 
direct effect in myeloma cells themselves. The findings in the present study identifies MPO as a 
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